Interacciones de Adalimumab

The concomitant use of a TNF blocker and abatacept or anakinra was associated with a higher risk of serious infections in patients with rheumatoid arthritis (RA); therefore, the concomitant use of Adalimumab-fkjp and these biologic products is not recommended in the treatment of patients with RA [see Warnings and Precautions (5.7 , 5.11) and Drug Interactions… (etiqueta de Adalimumab, Advertencias y precauciones)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (etiqueta de Captopril, Advertencias)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

Immunosuppressant/neoplastic: everolimus Co-administration of everolimus and PREZISTA/ritonavir is not recommended. irinotecan Discontinue PREZISTA/ritonavir at least 1 week prior to starting irinotecan therapy. (etiqueta de Darunavir, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (etiqueta de Itraconazol, Interacciones medicamentosas)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

…methylergonovine • HMG-CoA reductase inhibitors: lovastatin, simvastatin (these drugs can be temporarily discontinued to allow PAXLOVID use [see Table 2 , Drug Interactions (7.3) ] ) • Immunosuppressants: voclosporin • Microsomal triglyceride transfer protein inhibitor: lomitapide • Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists:… (etiqueta de Nirmatrelvir y ritonavir, Contraindicaciones)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (etiqueta de Ruxolitinib, Advertencias y precauciones)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (etiqueta de Adalimumab, Advertencia en recuadro)

Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route… (etiqueta de Ácido fenofíbrico, Interacciones medicamentosas)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (etiqueta de Adalimumab, Interacciones medicamentosas)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (etiqueta de Adalimumab, Interacciones medicamentosas)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etiqueta de Amlodipino, Interacciones medicamentosas)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etiqueta de Amlodipino y atorvastatina, Interacciones medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etiqueta de Amlodipino y olmesartán, Interacciones medicamentosas)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when coadministered. (etiqueta de Amlodipino y valsartán, Interacciones medicamentosas)

Immunosuppressants: cyclosporine, sirolimus, tacrolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for these immunosuppressants when coadministered with REYATAZ. (etiqueta de Atazanavir, Interacciones medicamentosas)

Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (etiqueta de Adalimumab, Interacciones medicamentosas)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (etiqueta de Adalimumab, Interacciones medicamentosas)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (etiqueta de Adalimumab, Interacciones medicamentosas)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (etiqueta de Adalimumab, Interacciones medicamentosas)

• Invasive fungal infections: For patients who develop a systemic illness on Adalimumab-fkjp, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. (etiqueta de Adalimumab, Advertencias y precauciones)

Therapeutic drug monitoring is recommended with concomitant use Immunosuppressant /neoplastic: everolimus ↑ immunosuppressants Co-administration of everolimus and PREZCOBIX or PREZCOBIX PED is not recommended. irinotecan Discontinue PREZCOBIX or PREZCOBIX PED at least 1 week prior to starting irinotecan therapy. (etiqueta de Darunavir y cobicistat, Interacciones medicamentosas)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (etiqueta de Denosumab, Advertencias y precauciones)

• Invasive fungal infections: For patients who develop a systemic illness on Adalimumab-fkjp, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. (etiqueta de Adalimumab, Advertencias y precauciones)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus and others metabolized by CYP3A ↓ immunosuppressant Dose adjustments of the immunosuppressant may be required. (etiqueta de Efavirenz, Interacciones medicamentosas)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus, and others metabolized by CYP3A ↓ immunosuppressant Dose adjustments of the immunosuppressant may be required. (etiqueta de Efavirenz, lamivudina y tenofovir, Interacciones medicamentosas)

Immuno-suppressants: e.g., cyclosporine (CsA) sirolimus tacrolimus ↑ immuno-suppressants ↑ elvitegravir (with CsA) ↑ cobicistat (with CsA) Therapeutic monitoring of the immunosuppressive agents is recommended upon coadministration with GENVOYA. (etiqueta de Elvitegravir, cobicistat, emtricitabina y tenofovir, Interacciones medicamentosas)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (etiqueta de Adalimumab, Interacciones medicamentosas)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (etiqueta de Etravirina, Interacciones medicamentosas)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (etiqueta de Adalimumab, Interacciones medicamentosas)

Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (etiqueta de Fenofibrato, Interacciones medicamentosas)

• Invasive fungal infections: For patients who develop a systemic illness on Adalimumab-fkjp, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. (etiqueta de Adalimumab, Advertencias y precauciones)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus ↑ Immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents. (etiqueta de Fosamprenavir, Interacciones medicamentosas)

• Invasive fungal infections: For patients who develop a systemic illness on Adalimumab-fkjp, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. (etiqueta de Adalimumab, Advertencias y precauciones)

HBV reactivation has also been reported in patients receiving certain immunosuppressants or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (etiqueta de Ledipasvir y sofosbuvir, Advertencias y precauciones)

Immunosuppressants: e.g. cyclosporine, tacrolimus, sirolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with KALETRA. (etiqueta de Lopinavir y ritonavir, Interacciones medicamentosas)

• Invasive fungal infections: For patients who develop a systemic illness on Adalimumab-fkjp, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. (etiqueta de Adalimumab, Advertencias y precauciones)

Immunosuppressive Agents There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. (etiqueta de Nefazodona, Interacciones medicamentosas)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (etiqueta de Nevirapina, Interacciones medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etiqueta de Olmesartán, amlodipino e hidroclorotiazida, Interacciones medicamentosas)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (etiqueta de Adalimumab, Interacciones medicamentosas)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (etiqueta de Penicilamina, Advertencias)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (etiqueta de Adalimumab, Interacciones medicamentosas)

• Invasive fungal infections: For patients who develop a systemic illness on Adalimumab-fkjp, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. (etiqueta de Adalimumab, Advertencias y precauciones)

Glipizide Decrease exposure Immunosuppressive Agents Cyclosporine Decrease exposure Tacrolimus Prevention or Management: Monitoring of whole blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when rifampin and tacrolimus are used concomitantly. (etiqueta de Rifampicina, Interacciones medicamentosas)

…Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine… (etiqueta de Rifapentina, Interacciones medicamentosas)

Immunosuppressants: cyclosporine, tacrolimus, sirolimus (rapamycin) ↑ immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with ritonavir. (etiqueta de Ritonavir, Interacciones medicamentosas)

HBV reactivation has also been reported in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (etiqueta de Sofosbuvir y velpatasvir, Advertencias y precauciones)

In controlled trials of other TNF blockers in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener’s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group. (etiqueta de Adalimumab, Advertencias y precauciones)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etiqueta de Telmisartán y amlodipino, Interacciones medicamentosas)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (etiqueta de Adalimumab, Interacciones medicamentosas)

Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs ( 7.1 ) (etiqueta de Tinidazol, Interacciones medicamentosas)

• Invasive fungal infections: For patients who develop a systemic illness on Adalimumab-fkjp, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. (etiqueta de Adalimumab, Advertencias y precauciones)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (etiqueta de Adalimumab, Interacciones medicamentosas)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persists despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etiqueta de Atorvastatina, Advertencias y precauciones)

Thirty-four patients were treated with corticosteroids and one patient was treated with a non-steroidal immunosuppressant. (etiqueta de Axitinib, Advertencias y precauciones)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (etiqueta de Ezetimiba y simvastatina, Advertencias y precauciones)

IMNM is characterized by proximal muscle weakness and elevated serum CK, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement with immunosuppressive agents. (etiqueta de Fluvastatina, Advertencias y precauciones)

IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etiqueta de Lovastatina, Advertencias)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (etiqueta de Metimazol, Advertencias)

Immunosuppressive Drugs Tacrolimus: Tacrolimus has been shown to be metabolized via the CYP3A system. (etiqueta de Nifedipino, Precauciones)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etiqueta de Pitavastatina, Advertencias y precauciones)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etiqueta de Pravastatina, Advertencias y precauciones)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (etiqueta de Propiltiouracilo, Advertencias)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etiqueta de Rosuvastatina, Advertencias y precauciones)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (etiqueta de Simvastatina, Advertencias y precauciones)

…Repaglinide, Rosiglitazone: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Insulin Insulin: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Immunosuppressants: Cyclosporine Use With Caution Cyclosporine: There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with cyclosporine. (etiqueta de Claritromicina, Interacciones medicamentosas)